Halberd Corp (OTC: HALB) Announces Breakthrough in Candida Auris Treatment

Halberd Corporation (OTC: HALB) a leading provider of innovative healthcare solutions, announces a breakthrough in the development of a treatment for Candida Auris infections. Halberd Demonstrates Eradication of Candida Auris Fungus in 5 minutes at Youngstown State University (YSU). Candida Auris is one of the antibiotic resistant infectious pathogens sent by the CDC (Centers for Disease Control and Prevention) to Youngstown State University (YSU) for testing.

Trading Activity

The stock went up as much as 19.09% in the intra-day session with a massive volume of 5,063,261. Moreover, in after-hours, volume stood at 2,039,918.

Over the course of the past year, Halberd Corporation has emerged as one of the more interesting companies in the healthcare space due to the sort of research it has conducted during the period. The innovative healthcare solutions providing company had been in the news earlier on in the month on February 13 when it announced that it had been successful in making a significant breakthrough.

The breakthrough in question was with regard to the development of a treatment meant to address Candida auris infections. As it happens, Candida auris is one of the antibiotic-resistant pathogens that had been sent for testing to Youngstown State University for testing by the Centers for Disease Control and Prevention (CDC).

Youngstown State University was the scientific partner of Halberd in the exercise. The company has developed its own method known as the extracorporeal method by way of which it eradicates antibiotic-resistant pathogens. It used the same method for the eradication of the Candida auris infections pathogen.

Another reason why it was a major new development for the company was the fact that in recent times Candida auris emerged as a major new threat to public health. It is resistant to multiple drugs and can cause serious infections in those who are infected by it. On top of that, it is also associated with high mortality rates.

Professor Dr. Cooper at the Department of Chemical and Biological Sciences at Youngstown State University spoke about the latest development as well. He noted that the innovative approach from Halberd provided a considerably effective solution to the treatment of patients who may be suffering from the effects of the Candida auris pathogen infection. It is now going to be interesting to see if the Halberd stock can come onto the radars of investors in the coming days.